Posted by Adam Awdish on
Innovative Grade US Origin Mouse C57BL6 Plasma from Innovative Research was used in the following study:
K. K. DurgaRao Viswanadham, Roland Böttger, Lukas Hohenwarter, Anne Nguyen, Elham Rouhollahi, Alexander Smith, Yi-Hsuan Tsai, Yuan-Yu Chang, Christopher Llynard Ortiz, Lee-Wei Yang, Liliana Jimenez, Siyuan Li, Chan Hur, and Shyh-Dar Li
June 22, 2021
Many injuries and diseases may lead to patients experiencing acute pain as a symptom, and a majority of surgery and trauma patients experience severe or intolerable pain that has the potential to result in chronic pain. Chronic pain is defined as pain that persists for more than three months, and it affects close to half of the world’s population and is the leading cause for patients seeking medical attention across the globe.
Opioids are painkillers that treat severe pain by binding to at least one opioid receptor (OR) and activating it. Major ORs include the mu opioid receptor (MOR), delta opioid receptor (DOR), and the kappa opioid receptor (KOR). Unfortunately, opioids can have serious side effects such as breathing and central nervous system suppression, which leads to nearly 70,000 annual deaths related to opiates around the world. Extensive research has attempted to develop novel analgesics, however current MOR-activating therapeutics such as morphine are still the most used pain treatments to date.
Researchers in this study developed and studied a library of MOR analogs, each with small hydrophobic modifications. Their tests showed that one analog, KK-103, had longer-lasting effects than morphine without inducing breathing suppression, physical dependence, or building tolerance. This shows that KK-103 may have potential as a safer and more effective analgesic for pain treatment than morphine.
Related products available from Innovative Research also include: